trending Market Intelligence /marketintelligence/en/news-insights/trending/fs8najqic6p4r2kezgovfw2 content esgSubNav
In This List

Homology Medicines prices IPO

Blog

Insight Weekly: Private equity slows; SPAC underwriters retreat; carbon capture boost

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms


Homology Medicines prices IPO

Homology Medicines, Inc. priced its IPO of 9 million common shares at $16 per share.

The Bedford, Mass.-based genetic medicines company granted the underwriters an option to buy up to an additional 1,350,000 shares.

Homology's common stock is expected to start trading on the Nasdaq Global Select Market on March 28 under the ticker symbol FIXX.

Bank of America Merrill Lynch, Cowen and Evercore ISI are acting as joint book-running managers, while BTIG is acting as the lead manager for the offering.